Laninamivir , 100% , 203120-17-6
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB736.80 | In Stock |
|
| 10mg | RMB1053.60 | In Stock |
|
| 25mg | RMB1773.60 | In Stock |
|
| 50mg | RMB3189.60 | In Stock |
|
| 100mg | RMB4653.60 | In Stock |
|
| 200mg | RMB6980.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >300°C (dec.) |
| Density | 1.61 |
| storage temp. | -20°C Freezer |
| solubility | Water (Slightly) |
| pka | 3.81±0.70(Predicted) |
| form | Solid |
| color | White to Off-White |
| Water Solubility | Water : 5 mg/mL (14.44 mM; Need ultrasonic) |
Description and Uses
Laninamivir octanoate (CS-8958), an ester prodrug form of the neuraminidase (NA) inhibitor laninamivir (R-125489), was approved in Japan in 2010 for treatment of influenza virus infections. Laninamivir octanoate is given by intranasal administration at a 20 mg or 40 mg dose. It has a long half-life in humans such that efficacy can be achieved after only a single dose. In addition to vaccines for immunoprophylaxis, antiviral drugs play an essential role in the treatment of influenza virus infections. Two viral proteins have been targeted for therapeutic intervention: the M2 ion channel and NA.
A new potent labelled neuraminidase
